Literature DB >> 7889536

pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.

M Correale1, I Abbate, A Paradiso, F Schittulli, C D Dragone, T Tedone, G Gargano, A M Catino, M D Musci, M De Lena.   

Abstract

Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7889536     DOI： 10.1007/bf03033869

Source DB:  PubMed          Journal:  Cell Biophys        ISSN： 0163-4992


  23 in total

1.  Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence.

Authors:  M Berry; A M Nunez; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7.

Authors:  S B Jakowlew; R Breathnach; J M Jeltsch; P Masiakowski; P Chambon
Journal:  Nucleic Acids Res       Date:  1984-03-26       Impact factor: 16.971

3.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

Authors:  P Masiakowski; R Breathnach; J Bloch; F Gannon; A Krust; P Chambon
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

4.  Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.

Authors:  M C Rio; J P Bellocq; B Gairard; U B Rasmussen; A Krust; C Koehl; H Calderoli; V Schiff; R Renaud; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.

Authors:  M C Rio; J P Bellocq; J Y Daniel; C Tomasetto; R Lathe; M P Chenard; A Batzenschlager; P Chambon
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

6.  Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.

Authors:  M Correale; A Paradiso; I Abbate; A Mangia; C D Dragone; T Tedone; R Filotico; F Schittulli; M De Lena
Journal:  Tumour Biol       Date:  1993

7.  Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy.

Authors:  J Predine; F Spyratos; J F Prud'homme; C Andrieu; K Hacene; M Brunet; C Pallud; E Milgrom
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

8.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

Authors:  L H Schwartz; F C Koerner; S M Edgerton; J M Sawicka; M C Rio; J P Bellocq; P Chambon; A D Thor
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

9.  [Primary structure of human protein pS2].

Authors:  M C Rio; P Lepage; P Diemunsch; C Roitsch; P Chambon
Journal:  C R Acad Sci III       Date:  1988

10.  Characterization of laboratory working standard for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation on breast cancer biopsies. Italian Committee for Hormone Receptor Assays Standardization.

Authors:  A Piffanelli; D Pelizzola; G Giovannini; L Catozzi; L Faggioli; M Giganti
Journal:  Tumori       Date:  1989-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.